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1. INTRODUCTION 
 Acne vulgaris is a chronic inflammatory disease of pilosebaceous 
units.  It is a common skin disorder affecting both boys and girls in the adolescent 
age group and also extends into the post adolescent age group. 
  Commonly it is due to formation of obstructing horny plugs in hair 
follicles, resulting in inflammation around the hair follicles, causing tissue 
destruction and scar formation. 
  This problem is present universally and affects people of all socio 
economic groups. With the improvement in the living status, awareness about 
acne is more among the affected age group causing psychological problems too. 
 From time immemorial, various remedies have been suggested and 
followed by Ayurvedic, Siddha, Unani practitioners and native healers present in 
various parts of the world. 
 The scientific evidence of improvement has not been documented 
yet.  Modern medicine also prescribes various drugs, which have been found to 
be useful in controlling this disorder. All of them have been found to be useful to 
various extents.  
 Topical drug therapy has been the mainstay and some drugs, for 
example, tetracycline is given orally. 
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 Since the condition results in scar formation and disfigurement in 
young boys and girls, it is associated with psychological problems causing great 
distress. 
 In this study an attempt has been made to evaluate the efficacy of 
a low dose oral Clindamycin in Acne vulgaris and the results of the study have 
been presented in ensuing chapters. 
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2. SCOPE OF THE STUDY 
  At present drugs are used topically in the form of gels, creams and 
alcohol-based lotions. The drugs used topically are antimicrobials and 
comedolytics. 
  Antimicrobial drugs are used orally. The antimicrobials 
administered orally are Tetracycline, Minocycline, Erythromycin and Doxycycline. 
 Since these oral antibiotics should be administered for more than 
two months, the incidences of adverse effects are also greater. 
 To mention, the risk of intracranial hypertension is more with the 
use of tetracycline orally for more than two months. 1 
 Apart from this, other adverse reactions like super infection, Liver 
and kidney damage and other forms of skin reaction are also common. 
 Clindamycin is a lincosamide antibiotic which inhibits protein 
synthesis by binding to 50s ribosome.It is a semisynthetic antibiotic and derived 
from lincomycin by the addition of chloride.  
            The distinctive feature is its high activity against a variety of 
anaerobes. The usual oral dose is 150-300mgs 4 times a day for anaerobic 
infections. For Acne vulgaris topical clindamycin is found to be very effective.  
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 The efficacy of oral clindamycin has not been evaluated, since high 
doses of 150-300 mgs given four times a day,  causes  pseudomembranous 
entero colitis due to clostridium difficle. This clindamycin is effective against 
propionibacterium acne that has been found to colonize the acne lesions. 
 Clindamycin has been used topically and is found to be effective. 
Therefore a study to evaluate a low dose of oral clindamycin in acne vulgaris was 
proposed and taken up. In this low dose, the beneficial effects without the risk of 
pseudomembranous colitis and other possible adverse effects have been 
evaluated. 
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3. AIM OF THE STUDY 
Aim of the study is to evaluate the  
¾ Efficay of oral clindamycin in comparison with doxycyclin in mild to 
modearte cases of acne vulgaris. 
¾ Safety of oral clindamycin in comparison with doxycyclin in mild to 
modearte cases of acne vulgaris.  
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4.1. ACNE VULGARIS 
 Acne vulgaris is a common skin disorder. About 70%_80% of 
people ,suffer from some sort of acne at one time or other. 2 
                      Acne vulgaris is prevalent in the age group 12-25 years.Though it is 
viewed as physiological reaction, the inflammatory changes which occur is 
disabling socially.3 
 Beyond the age of 23, Acne vulgaris seems to be more Prevalent 
among women.4 
AETIOPATHOGENESIS 
  Acne vulgaris is a disease of pilosebaceous follicles. This is found 
maximally in face, chest and back. These are the primary sites of involvement. 
The basic cause is not known, and clinical Acne is due to interaction of various 
causes. 
  The earliest feature is increased sebum secretion; this is followed 
by formation of comedones or black heads. This comedones are follicular plugs 
made up of follicular debris and compacted sebum.5  
  The comedones have a pigmented tip caused by melanin 
deposition. Next there is colonization of pilosebaceous duct with propioni 
bacterium acne.  
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                    This is followed by inflammation in which reddened papules develop 
from the blocked follicles. They are tender and some times develope pus under 
the tips. 
  Propionibacterium acnes is non motile but easily colonizes the 
duct. To colonize, p.acnes organisms must clump; free fatty acids aid clumping, 
and so bacterial lipases may be nessary for clumping and duct colonization.6  
  Propionibacterium species are anaerobic coryne bacteria,reside in  
normal skin. Propionibacterium acnes,is aerotolerant and grows aerobically.It  
participates in the pathogenesis of acne by producing lipases that split free fatty 
 acids off from skin lipids.These fatty acids can produce tissue inflammation and 
 contribute to acne.7  
I                          
                      Recent studies have shown that P.acnes binds to the  receptors on 
monocytes and neutrophils then leads to the production of multiple 
Proinflammatory  cytokines including  interleukin12 ( IL12), interleukin 8 ( IL 8) 
and tumor necrosis factor ( TNF)which in turn produces inflamation.8 
 
 9
The Four basic changes in acne vulgaris are  
¾ Abnormal follicular keratinization and plugging of follicles along with 
increased sebum production. 
¾ Comedogenesis. 
¾ Colonization of duct with propionibacterium Acne. 
¾ Inflammation. 9 
  In severe cases central liquefaction occurs in the nodules, resulting 
in the formation of fluctuant cyst. The cysts have no real epithelial lining; so they 
are pseudocysts. When this nodules and cysts eventually subside they leave 
nodular scars,sometimes becoming hypertrophic or even keloidal. 
  Though the common areas are, lower jaw, chin, nose and 
forehead, in severe cases outer aspect of upper arms, buttocks and thighs are 
also involved. 
  Many factors are said to contribute like genetic factors, androgenic 
stimulation at the time of puberty and bacterial colonization as mentioned before. 
  Androgenic stimulation leads enlarged sebaceous glands with 
increased sebum production in both sexes. 
  It has also been found out that many patients with acne vulgaris do 
not have circulating androgens at pathological level. 10 
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  There may be an end organ sensitivity of the sebaceous glands to 
androgen stimulation or even that the circulating androgens are converted to a 
more potent androgen with in the sebaceous glands.11           
  Pathogenic bacteria are not found in Acne vulgaris. Only normal 
flora has a role to play. 
  The flora consists of Gram negative cocci like Staphylococcal 
Epidermidis, Gram -positive bacteria like Propionibacterium acne and also yeast 
like micro- organism known as pityriosporum ovale.  
  These known to colonize the sebaceous follicles and the Propioni 
bacterium is being most abundant. 
4.2. BACTERIAL FLORA IN ACNE 
 Acne is not infectious; three major organisms isolated from the  
surface of the skin and pilosebaceous ducts of patients with Acne are; 
4.2.1. Propioni bacterium Acne. 
4.2.2. Staphylococcal epidermidis. 
4.2.3. Pityriosporum ovale.12 
  Three major sub groups of Propioni bacterium acne are P. acnes, 
P. granulosum and P. avidum. Of this Propioni bacterium acnes is most important 
and to a lesser extent P.granulosum. These organisms live in association with 
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Staph epidermidis and M.furfur, the later organism have some control over the 
growth of P.acnes.13 
  It is possible that the number of microorganisms increase at each 
stage as the follicle progresses from normal to comedone and on to an inflamed 
lesion.  The metabolic product includes propionic acid from which the genus 
name, Propioni bacterium derives . 
4.2.1. PROPIONI BACTERIUM ACNES  
 It is an anaerobic corynebacterium and can also grow aerobically. It 
is a gram positive and nonmotile anaerobic bacteria.  
  It participates in the pathogenesis of Acne by producing lipases that 
split free fatty acids from skin lipid. 
 In adolescents there is increased seborrhoea and this is associated 
with significant increases in Grampositive nonmotile Propioni bacterium Acne. 
  The Propionibacterium acne is microaerophilic and lipophilic and 
therefore they live in depth of hair follicles in an oily milieu and they increase in 
number during puberty when the sebum secretion is also increased.14               
  The normal follicular flora may also be responsible for hydrolyzing 
the lipid esters of sebum, liberating potentially irritating fatty acids                
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The constituents of sebum and of skin surface lipid after the 
bacterial hydrolysis are as follow.   
 
 
 
 
 
 
   
 
 
 
  In gram stain, they are highly pleomorphic,showing curved,clubbed 
or pointed ends.  
  The dermal inflammation is not caused by bacteria but results from 
biologically active mediators they diffuse from follicle.  
  These mediators are produced by P.acnes. This bacteria brings 
about hydrolysis of lipid esters in sebum causing liberation of irritating fatty acids. 
Sebum 
     Triglycerides 
     Cholesterol ester 
     Squalene 
     Wax esters 
Skin surface lipid 
     Sebum lipids 
     Fatty acids 
     Monoglycerides 
     Diglycerides 15 
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  In vitro P.acnes produces many enzymes including three 
proteases, lipid phosphatases and hyaluronate lyase,all of which split protein and 
are implicated in the development of inflammation.16  
 4.2.2. Staphylococcus Epidermidis  
 The genus Staphylococcus has about 30 species; the clinically 
important ones are Staph. aureus, Staph. epidermidis, Staph. saprophyticus. 
 Staph.epidermidis are gram positive,nonpigmented coagulase 
negative cocci . 
 In infections due to implanted appliances and devices about 75% 
are caused by coagulase negative Staphylococcus epidermidis.17 
  Staph epidermidis is more resistant to antimicrobial drugs than is 
Staph aureus  S. epidermidis infections are mostly hospital acquired.  
  The predisposing factors for Staph epidermidis infections are 
instrumentation procedures like catheterisation, heart valve implantations etc   It 
has been found to cause infections in people who are immuno compromised and 
those who are on immuno suppressive therapy.18 
                       Staphylococci are classified into slim produces and non slim 
produces.The ability to produce slim has been proposed as a marker for 
pathogenic strains of staphylococci.   
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                        Staph epidermidis produces a substance called slim.19 This is a 
viscus extracellular glyco conjugate that allows Staph epidermidis to adhere to 
smooth surfaces such as prosthetic medical devices and the catheters. 
  Scanning electran microscopy has demonstrated that biofilms 
consisting of staphylococci encased in a slime matrix are formed in association 
with biomaterial associated infections.                                  
  Slime has been found to inhibit neutrophil chemotaxis, 
phagocytosis and the antimicrobial agents like  vancomycin and Teicoplanin. 
4.3. Basic Principles of treatment 
Treatment may be aimed at 
¾ Reducing the bacterial population of the hairfollicles to cutdown the 
hydrolysis of lipids – Antimicrobial agents.20 
¾ Encouraging the shedding of the follicular horny plugs to free the 
obstruction – Comedolytic agents. 
¾ Reducing the rate of sebum production, either directly by acting on the 
sebaceous Glands or indirectly by inhibiting the effects of androgens on 
the sebaceous glands –Anti androgens. 
¾ Reducing the damaging effects of acne inflammation on the skin with anti 
inflammatory agents.                             
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4.4. Drug Therapy for Acne vulgaris 
4.4.1. Topical agents used are,   
 4.4.1.1. Benzoyl Peroxide 
 4.4.1.2. Tretinoin. 
 4.4.1.3. Adapalene. 
 4.4.1.4. Topical antibiotics. 
 4.4.1.5. Azelaic acid. 
4.4.1.1. BENZOYL  PEROXIDE  
 The most widely used topical drug is benzoyl  peroxide, either as 
monotherapy or in combination. It reduces the number of non inflamed lesions.  
                       It penetrates the stratum corneum or follicular openings and is 
converted metabolically to benzoic acid with in the epidermis and dermis.21 
  It is primarily antimicrobial and rapidly reduces both surface and 
ductal P.acnes. It acts by liberating oxygen and thus kills the organisms. It has 
high efficacy against P.acnes and has additional keratolytic and comdolytic 
properties.22 
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    Organisms do not develop resistance to Benzoyl peroxide and it is 
mild irritant. It is used as 5% or 10% cream, Gel or lotion. It is effective in both 
inflammatory and non inflammatory Acne.  
 Benzoyl peroxide reduces the incidences of drug resistance when 
used in combination with antibiotics. 
4.4.1.2. TRETINOIN 
  It is a comedolytic agent. It produces lysis of Keratinocytes and this 
Prevents formation of comedons. It has no antibacterial effect. It is used as 
Cream 0.025% to .05%  and  0.1% , as a gel 0.01% and 0.025%.  This can be 
alternated with Benzoyl peroxide. Retinoids are teratogenic and is contraindicated 
during pregnancy.23 
 Because it can be irritating on the skin, starting therapy with a lower 
concentration,less irritating cream and gradually working upto the more irritating 
gel and liquid forms makes patient compliance easier. 
4.4.1.3. ADAPALENE  
  It is effective topical retinoid and has predominant anti comidonal 
activity.  It binds to nuclear retinoic acid receptor and modulates keratinization 
and differentiation of follicular epithelial cells. Also it has anti-inflammatory action. 
It is as effective but less irritating than tretinoin and is available as 0.1% Gel.24 
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4.4.1.4. TOPICAL ANTIBIOTICS  
¾ Tetracycline  2%     -  Less effective. 
¾ Erythromycin 1-2%  - quite effective for mild and moderate type of Acne. 
¾ Clindamycin   2%    - quite effective for mild and moderate type of Acne. 
  They are appropriate for cases with inflamed papules but less 
effective in non inflamed comedon formation in acnevulgaris. These antibiotics 
have low tendancy to sensitize and are not responsible for allergic contact 
dermatitis, though they may cause a minor degree of direct primary irritation. 
                     Bacterial resistance to erythromycin frequently develops so it is 
used less often than other treatments.25 
3.4.1.5. AZELAIC ACID  
  This is obtained from a natural product pityriasporum ovale. It is a 
straight chain saturated dicarboxilic acid effective in the treatment of acne 
vulgaris.26 
                       It reduces cutaneous bacterial density, free fatty acid content of 
skin surface lipids and proliferation of keratinocytes.27 It is used as 10% or 20% 
cream. Also it has anticomedogenic property. 
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4.4.2. SYSTEMIC THERAPY  
Drugs used in Systemic Therapy and given orally are, 
 3.4.2.1. Antibiotics. 
 3.4.2.2. Oestrogen. 
 3.4.2.3. Isotretinoin. 
 3.4.2.4. Anti androgen.27 
4.4.2.1. ANTIBIOTICS  
 Oral antibiotics are the most widely prescribed oral therapy world 
wide. Tetracycline is one of the drug which is commonly prescribed for acne 
vulgaris. 
  Oxytetracycline and Tetracyline are given dose of 250 mgs three 
times a day. The improvement usually begins only 4-8 wks after the 
commencement of treatment. Treatment may have to be maintained for several 
months. 
  Tetracyclines cause gastrointestinal discomfort, Diarrhoea and are 
teratogenic in pregnant women.28 
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4.4.2.1.1. DOXYCYCLINE  
  Doxycycline belongs to tetracycline group of antibiotics. It is an 
active congener of tetracycline. It is one of the most commonly prescribed 
antibiotics for the treatment of acne vulgaris, though oxytetracycline and 
tetracycline are also used for acne vulgaris among tetracyclines.29 
  MECHANISM OF ACTION 
  Doxycycline inhibit bacterial protein synthesis by binding to the 
30s subunit of the ribosome and preventing access of amino acyl-tRNA to the 
mRNA-ribosome complex at the acceptor site. Thus it inhibits bacterial protein 
synthesis. It is bacteriostatic in action. 
  Doxycycline enters the gram negative bacteria through passive 
diffusion through the hydrophilic channels formed by the porin proteins of the 
outer cell membrane. But it enters into the gram positive bacteria by an active 
transport by an energy dependent system that pumps it across the cytoplasmic 
membrane.29 
PHARMACOKINETICS 
  Among all tetracyclines, doxycycline has got highest oral 
absorption (95%). However, taking it concomitantly with dairy foods decreases 
absorption because of the formation of non-absorbable chelates with calcium 
ions. Non absorbable chelates are also formed with other divalent and bivalent 
cations like Magnesium and Aluminium antacids. 
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  Doxycycline is  metabolized in liver to form soluble glucuronides. 
Most tetracyclines are excreted through kidney and are contraindicated in renal 
failure. But doxycycline is excreted through bile into the intestine. So it can be 
used in renal failure patients also.29 
 
ADVERSE EFFECTS: 
  Adverse effects with doxycycline are few like nausea and vomiting 
usually not serious. Gastrointestinal discomfort and diarrhea occasionally occur. 
Photosensitivity is a problem only with old tetracyclines not with doxycycline.  
PRECAUTIONS  
                         It should be used with caution in patients with hepatic dysfunction 
and in conjuction with alcohol and other hepatotoxic drugs. It should not be given 
to pregnant women as it is teratogenic. It also causes bone and tooth 
abnormalities in children. 
4.4.2.1.3. ERYTHROMYCIN   
  It is a macrolide antibiotic and a bacteriocidal drug. In acne it is 
effective as similar to tetracycline. Effective mostly against Gram positive and few 
Gram negative organisms. It causes inhibition of bacterial protein synthesis via 
binding to the 50s ribosomal RNA.. Erythromycin is preferable in the female who 
is or might, become pregnant or is breast feeding .30 
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  Dose is 250 mg Q 6th hrly for first few weeks. Adverse effects like 
epigastric distress, hepatitis with cholestatic Jaundice. It can causes inhibition of 
CYP 3A4 when given along with Terfenadine, Astemizole and Cisapride. 
4.4.2.1.5. CLINDAMYCIN   
  Clindamycin is a semisynthetic derivative of lincomycin. Chemically  
it is a derivative of trans-L-4-n propylhygrinic acid, attached to sulphur containing 
derivative of an octose. 31 
CHEMICAL STRUCTURE OF CLINDAMYCIN  
 
 
 
 
 
 
 
 
 
 
Clindamycin 
Methyl-6-amino-7-chloro-6,7,8-trideoxy-N- 
[(2S,4R)-1-methyl-4-propylprolyl]- 
1-thio-β-L-threo-D-galacto-octopyranoside 
IUPAC name  
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MECHANISM OF ACTION  
  It binds to 50s ribosomal subunit of bacteria and suppresses 
protein synthesis. Mechanism of action resemble erythromycin and 
Chloramphenicol, though they are  not structurally related. They act at site with in 
close proximity,and binding by one of these antibiotics to the ribosome may inhibit 
the interaction of the others.  
  It inhibits more Gram positive cocci including penicillinase 
producing staphyllococcus but not methicillin producing Staphylococcus and 
other Gram positive organisms like Clostridium Diphtheria, Nocardia, 
Actinomycosis  and  Toxoplasma. 
  The distringtive feature is its high activity against anaerobes 
especially bacteroides fragilis. It is not active against anaerobic Gram negative 
bacilli.31 
PHARMACOKINETICS 
  It is given orally, well absorbed and food does not reduce the 
absorption.The plasma half life( t½) of 150 mg given orally is 2.9 hrs and usually 
given at  6th hourly intervals. 
         It is widely distributed in body fluids and tissues including bone but 
CSF concentration is poor.31 
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   Clindamycin accumulates in polymorphonuclear leucocytes, 
alveolar  macrophages and abscesses. It is demethylated to inactive metabolites 
and  excreted in urine and bile. 
AVAILABILITY   
  It is available as 150 mg and 300mg capsules. Injections of      
300mg/2mland 600 mg/4ml is also available. The preparation which is given  
parenterally is phosphate ester which is rapidly hydrolysed to active parent 
compound in the body. 
  For Paediatric use, it is available as Clindamyein palmitate and it is    
an  inactive prodrug.31 
DOSAGE  
  Oral dosage is 150 – 300 mg every 6th hourly .For children 
clindamycin palmitate is 8 – 12 mg/kg/day in divided doses. 
 For serious infections caused by susceptible organisms the drug is 
given intravenously and intramuscularly in the dose of 600 – 1200 mg /day in two 
to four divided doses. 
INDICATIONS 
 Infection caused by anaerobic Gram positive cocci.32 
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 For Gram negative organisms. For this it is more effective when combine 
with     aminoglycoside. 
 Clindamycin given intravenously along with oral dose of pyremethamine 
has been found to be effective in encephalitis caused by Toxoplasma 
gondi in AIDS.32 
 Clindamycin combination with oral primaquine has been found to be useful 
for pneumocystitis carini infection in AIDS Patients 32 
 Clindamycin topical in the form of solution, gel or lotion are used for acne 
vulgaris caused by propionibacterium acne. 
 Clindamyin Vaginal Cream for bacterial Vaginosis. 
ADVERSE EFFECTS 
 It causes diarrhoea, pseudomembranous enterocolitis may occur due to 
clostridium difficle infection. 
  Patient present with abdominal pain, diarrhoea, fever and passage of 
mucous and blood in the stools, can be lethal. 
 Skin rashes can occur. 
 Rarely erythema multiforme. 
 Reversible elevation of Aspartate amino transferase and Alamine 
aminotransferase. 
 Granulocytopenia, thrombocytopenia. 
 Intravenous administration causes thrombophlebitis. 
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DRUG INTERACTIONS  
 Clinidamycin can inhibit neuromuscular transmission and potentiates the 
effect of Neuro musclear blockers 32 
 Drugs like opioids which reduce peristalsis, they prolong and worsen 
pseudomembrano entero colitis. 
4.4.2.2. OESTROGENS  
  It can be used in girls above 16 years. Ethinyloestrodiol is given at 
the dose of  35-50 µg/day from  5th to  25th day of the menstrual cycle.   
  It acts by suppressing Androgenic stimulation of sebaceous 
follicle.33 
  Their use is best restricted to women over 16 yrs old with 
recalcitrant severe pustolocystic acne. Side effects include nausea, weight gain, 
hypertension and thromboembolism.  
4.4.2.3. ISOTRETINOIN (13-CIS RETINOIC ACID) 
  It is orally administered retinoid. It reduces the production of sebum 
by shrinking the sebaceous glands. It has effect on the keratinization of the mouth 
of the hair follicle and an anti inflammatory action as well. The clearance of skin 
bacteria also occurs secondary to reduction in sebum production. 
                     The usual dose is 0.5 to 1 mg/ kg body weight per day for 16 weeks.  
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                     The adverse effects are dryness of skin, eyes, nose and mouth, 
cracking of lips, epistaxis, pruritus etc. Isotretinoin is also teratogenic drug.34 
                                It produces hepatotoxicity, bone toxicity, depression, psychosis and 
rarely suicidal thoughts or attempts. 
4.4.2.4. ANTI ANDROGEN   
  These drugs Inhibit androgenic activity and reduces sebum 
secretion. Reducing the rate of sebum production will lessen the tendency to form 
comedons and reduce the number of inflammatory lesions. 
  Cyproterone acetate, an antiandrogen is used at the dose of 
100mg on days  5 --15 of menstrual cycle. 
          Anti androgens are available as a mixture of Cyproterone acetate 
2mg an antiandrogen  with  oestrogen  ethinyl oestradiol  35µgm.35 
                        It competitively inhibits the testosterone receptors or androgenic 
receptors in target peripheral organs. It is not frequently used in Acnevulgaris 
therapy. It is not suitable for men because of its feminizing properties. 
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5. MATERIALS AND METHODS 
STUDY CENTER  
Out Patient Section, 
Department of Dermatology,  
Govt. Stanley Medical College & Hospital, Chennai. 
STUDY PERIOD  
September 2005 to May 2006. 
STUDY DURATION FOR EACH PATIENT                 
Total six weeks. 
Drug administration - four weeks. 
Follow up - two weeks. 
STUDY DESIGN 
Prospective, Randomized Controlled, Single blind study. 
DRUGS USED              
Capsule Clindamycin 50 mg. 
Capsule Doxycycline 100 mg. 
Benzoyl Peroxide 5 % topical cream.  
SOURCE OF DRUGS  
Capsule Clindamycin, supplied by Indi pharma, Ponda, Goa.  
  Capsule Doxycycline routinely available in the dispencery of Govt. 
  Stanley Medical College Hospital.    
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STUDY PLAN 
When the study was planned, it was first proposed to evaluate the 
safety and efficacy of oral Clindamycine with oral Doxycycline. 
On review the literature, Acne Vulgaris is found to have various 
steps in the pathogenesis and the drugs currently used act at different steps. 
Hence it was decided to include two more groups, in which the patients receiving 
oral Clindamycine along with topical Benzoyl peroxide are compared with another 
group receiving oral Doxycycline along with topical Benzoyl Peroxide . 
            This study in addition to giving information about the safety and 
efficacy of oral Clindamycine used in low doses,and also give valuable 
information about the efficacy rate,in combination with topical benzoyl peroxide. 
 
STUDY DESIGN 
 The Study was started after getting the approval from institutional 
ethical committee. 
 Patients were included only after obtaining the informed written 
consent. In patients who were less than 18 years old, the consent was obtained 
from parents also. A copy of the consent form is attached (Appendix I). 
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INCLUSION CRITERIA 
Patients who are  
¾ Having mild to moderate acne vulgaris with the lesions only on cheek, 
forehead, chin, nose and neck (above clavicle). 
¾ Both males and females of 15 years to 25 years. 
¾ Willing to give written informed consent. 
¾ Suffering from acne vulgaris for three or more months. 
¾ Not under drug therapy for acne vulgaris. 
¾ Not suffering from any systemic illness. 
 
EXCLUSION CRITERIA 
Patients who are  
¾ Having severe acne vulgaris  
¾ Below 15 years and above 25 years. 
¾ Suffering from systemic illness like cardiac valvular lesions, Diabetes 
mellitus, Hypertension and congenital anomalies. 
¾ Not willing to give informed written consent. 
¾ With the history of hypersensitivity to antimicrobials.  
 
METHODOLOGY 
  The study is conducted as four different trials. In each trial totally 60 
patients are selected and are randomly divided in to 2 groups, group A and B. 
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TRIAL I 
  In trial I, 60 patients suffering from mild acne vulgaris are included 
and are randomly allotted in to group A and B, with 30 patients in each group.  
  Group A patients are treated with oral Doxycycline 100 mg, once 
daily, in the morning, after food, for four weeks. Group B patients are treated with 
oral Clindamycin 50 mg  once daily in the morning, after food, for four weeks.   
  The patients are assessed before starting drug therapy and after 
drug administration, at the end of 1st week, 2nd week, 3rd week and at the end of 
4th week. 
  The patients are also assessed during the follow up visits at the 
end of 5th and 6th weeks. 
TRIAL II 
   In this trial also, 60 patients suffering from mild acne vulgaris are 
included and are randomly allotted in to group A and B, with 30 patients in each 
group. 
  But here, Group A patients are treated with 5% topical Benzoyl 
peroxide applied during bed time every day for 4 weeks, in addition to oral 
Doxycycline 100 mg given once daily, in the morning, after food, every day for 
four weeks. 
  Group B patients are treated with 5% topical Benzoyl peroxide 
applied during bed time every day for 4 weeks, in addition to oral clindamycin 50 
mg given once daily, in the morning, after food, every day for four weeks. 
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  The patients in both the groups are assessed before starting 
therapy and at the end of every week as done in Trial I. 
TRIAL III 
  In Trial III, 60 patients suffering from moderate acne vulgaris are 
included and are randomly allotted in to group A and B, with 30 patients in each 
group.  
  Group A patients are treated with oral Doxycycline 100 mg, once 
daily, in the morning, after food, every day for four weeks. Group B patients are 
treated with oral clindamycin 50 mg once daily in the morning, after food, every 
day for four weeks.   
  The patients are assessed before and after drug therapy in the 
similar way followed in trial I and II.  
 
TRIAL IV 
  In trial IV, like trial III, 60 patients suffering from moderate acne 
vulgaris are included and are randomly allotted in to group A and B, with 30 
patients in each group.  
  Here Group A patients are treated with 5% topical Benzoyl 
peroxide applied during bed time every day for 4 weeks, in addition to oral 
Doxycycline 100 mg given once daily, in the morning, after food, every day for 
four weeks. 
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  Group B patients are treated with 5% topical Benzoyl peroxide 
applied during bed time every day for 4 weeks, in addition to oral clindamycin 50 
mg given once daily, in the morning, after food, every day for four weeks. 
 
ASSESMENT CRITERIA 
  Acne vulgaris is classified into Grade I, II, II and IV depending upon 
the presence of comedons, papules and pustules. 
Grade I (mild)   – Comedons & occasional papules. 
Grade II (moderate)   – Comedons, papules & few pustules. 
Grade III (severe)   – Pustules, nodules & abscesses.  
Grade IV (cystic)   – Very severe form consists of cysts,     
     Abscesses & Scarring. 
 In this study, only grade I (mild) & grade II (moderate) patients are 
included and grade III and grade IV patients are not included. 
The effect of drugs in reducing the number of comedons, papules and 
pustules in all the four trial groups are recorded before starting treatment and at 
the end of every week for six weeks.  
 The model of proforma used for the study is given in the appendix  II.  
The results are assessed both clinically and statistically in all the four 
trials. 
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6. RESULTS 
                          The results of the study conducted to evaluate the safety and 
efficacy of oral dose of 50 mg of Clindamycin administered daily for a period of 
four weeks in comparision with oral Doxycycline are presented and analysed. 
                        The purpose of using topical Benzoyl peroxide 5% cream is to see 
if the benefit arising out of combination therapy is better than single drug therapy 
or not.  
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RESULTS OF TRIAL  I 
THE EFFECT OF DRUGS ON COMEDONS IN MILD CASES OF ACNE 
  When Doxycycline is administered orally for four weeks in 30 
patients, on zero visit that is before drug administration, the arithmetical mean of 
number of comedons was 4.40 and this has come down to 3.06 at the end of six 
weeks. 
S.No. visit 0 visit 1 visit 2 visit 3 visit 4 visit 5 visit 6 
1 4 4 4 4 3 3 4 
2 4 3 3 4 3 3 3 
3 5 3 3 4 3 4 4 
4 4 4 4 3 3 2 3 
5 5 3 3 4 4 4 2 
6 3 3 3 4 3 3 3 
7 5 5 4 2 3 4 3 
8 5 5 3 4 4 3 2 
9 4 4 3 4 2 2 3 
10 5 4 4 4 4 3 3 
11 4 3 4 2 3 3 4 
12 4 3 4 3 4 2 3 
13 4 5 5 3 3 3 4 
14 3 5 4 5 2 3 3 
15 5 4 3 3 3 4 2 
16 5 4 4 3 3 3 3 
17 5 5 4 4 2 4 3 
18 5 5 5 4 3 3 3 
19 4 4 4 3 3 2 4 
20 5 3 4 4 4 3 3 
21 4 4 4 3 4 3 4 
22 3 5 5 3 3 2 3 
23 5 4 3 4 4 3 2 
24 5 3 5 3 3 3 3 
25 4 5 5 3 4 4 3 
26 4 4 3 4 4 4 2 
27 5 3 3 3 3 3 3 
28 5 5 4 3 2 4 3 
29 4 4 4 3 3 3 4 
30 5 4 3 2 3 4 3 
Mean 4.4 4 3.8 3.4 3.16 3.13 3.06 
   
 Table 1 No. of comedons in each patient in group A of trial I 
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 In Clindamycin administered group, the arithmetical mean of 
number of comedons, 4.33 on ‘0’ visit that is before drug administration has come 
down to 2.83 after 6 weeks of drug administration. 
 
S.No. visit 0 visit 1 visit 2 visit 3 visit 4 visit 5 visit 6 
1 4 3 4 4 3 3 3 
2 5 3 5 4 4 2 4 
3 4 5 3 3 3 3 3 
4 4 1 4 3 2 3 2 
5 4 1 4 1 2 2 3 
6 3 4 3 4 2 3 3 
7 5 3 4 4 3 4 2 
8 5 3 4 3 3 3 4 
9 5 5 4 1 2 2 2 
10 5 1 1 3 4 3 4 
11 4 2 4 5 3 4 3 
12 5 4 4 3 4 3 3 
13 4 5 1 1 3 3 3 
14 3 5 4 4 2 4 4 
15 5 4 3 3 4 3 3 
16 5 3 2 2 4 2 2 
17 4 2 1 2 3 3 2 
18 4 5 3 3 4 4 4 
19 5 4 4 3 2 1 3 
20 5 3 3 4 3 3 2 
21 4 1 3 2 4 3 3 
22 5 4 4 1 3 4 3 
23 4 5 3 2 2 2 3 
24 3 4 1 3 4 2 2 
25 5 4 2 4 3 3 3 
26 5 2 3 3 1 4 2 
27 4 5 4 3 2 3 1 
28 4 4 2 3 2 3 4 
29 5 3 1 4 3 4 3 
30 3 5 4 3 2 3 2 
Mean 4.33 3.43 3.06 2.93 2.86 2.96 2.83 
        
 Table 2 No. of comedons in each patient in group B of trial I 
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THE EFFECT OF DRUGS ON PAPULES IN MILD CASES OF ACNE  
  In Doxycycline administered group the arithmetical mean of 
number of papules in 30 patients on ‘0’visit that is before drug administration was 
3.30 and it has come down to 2.2 at the end of sixth week . 
 
S.No. visit 0 visit 1 visit 2 visit 3 visit 4 visit 5 visit 6 
1 4 2 2 3 2 2 1 
2 4 3 1 2 3 3 2 
3 3 3 2 3 1 2 2 
4 4 2 1 3 3 1 2 
5 3 2 2 2 1 1 2 
6 4 3 3 3 2 3 3 
7 2 3 2 2 3 2 3 
8 3 2 3 1 1 3 2 
9 4 4 3 2 2 2 3 
10 2 2 3 1 2 3 1 
11 3 3 2 2 3 3 2 
12 4 3 4 3 1 2 3 
13 3 4 2 3 3 2 2 
14 3 2 4 1 2 3 2 
15 4 3 3 2 1 2 2 
16 4 2 2 3 3 3 3 
17 3 3 4 2 2 2 1 
18 4 3 3 3 2 2 2 
19 2 2 1 3 3 2 2 
20 3 3 2 3 2 2 3 
21 4 4 2 3 2 3 2 
22 3 3 2 2 3 2 2 
23 4 2 3 2 4 1 2 
24 4 3 2 3 3 2 3 
25 3 3 3 3 2 2 3 
26 4 2 2 2 2 2 2 
27 2 3 3 3 3 3 3 
28 3 2 2 1 2 2 3 
29 4 4 4 2 2 3 1 
30 2 2 3 2 2 0 2 
Mean 3.3 2.73 2.5 2.33 2.23 2.16 2.2 
        
 Table 3 No. of papules in each patient in group A of trial I  
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  In the case of Clindamycin administered group the arithmetical 
mean of number of the papules in 30 patients  on ‘0’ visit that is before drug 
administration was 3.36 and it has very significantly come down to 1.9 at the end 
of sixth visit. 
S.No. visit 0 visit 1 visit 2 visit 3 visit 4 visit 5 visit 6 
1 2 3 1 2 2 1 1 
2 3 2 2 3 3 3 2 
3 4 4 2 1 1 2 2 
4 2 2 3 2 2 1 3 
5 3 3 2 3 2 3 2 
6 4 3 2 1 3 2 0 
7 3 1 2 2 2 2 2 
8 3 2 2 2 3 1 1 
9 4 3 2 3 1 3 1 
10 4 2 3 1 0 0 2 
11 3 1 2 2 1 2 2 
12 4 3 2 2 1 1 3 
13 4 2 3 1 2 1 2 
14 3 3 1 2 1 2 2 
15 4 1 2 2 2 1 2 
16 4 3 2 2 2 2 2 
17 3 2 2 1 3 2 3 
18 4 3 2 2 1 3 3 
19 4 3 3 2 3 2 1 
20 3 2 2 3 2 3 0 
21 4 2 3 1 1 3 2 
22 2 2 2 2 3 1 2 
23 3 3 2 3 2 3 3 
24 4 3 2 3 2 2 2 
25 3 2 3 2 1 2 1 
26 3 2 2 4 2 3 2 
27 4 3 2 2 1 3 2 
28 3 2 2 1 3 1 2 
29 3 3 3 2 1 2 3 
30 4 2 0 3 2 1 2 
Mean 3.36 2.4 2.1 2.06 1.83 1.93 1.9 
        
 Table 4 No. of papules in each patient in group B of trial I  
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RESULTS OF TRIAL II 
THE EFFECT OF DRUGS ON COMEDONS IN MILD CASES OF ACNE 
                       The arithmetical mean of the number of comedons in one group of 
thirty patients who receive oral Doxycycline along with topical Benzoyl peroxide 
was 4.33 on ‘0’visit that is before starting therapy. The arithmetic mean at the end 
of sixth visit has come down to 2.0. 
S.No. visit 0 visit 1 visit 2 visit 3 visit 4 visit 5 visit 6 
1 4 4 3 3 3 3 3 
2 4 4 3 1 2 2 3 
3 3 3 4 3 3 2 0 
4 5 3 4 1 3 0 3 
5 5 5 4 2 4 3 1 
6 5 5 5 3 3 2 3 
7 5 4 4 1 4 3 2 
8 4 4 3 4 1 0 3 
9 5 5 2 4 2 3 1 
10 4 5 4 2 3 3 3 
11 3 4 3 1 0 4 2 
12 5 3 4 1 1 3 2 
13 5 4 3 2 3 0 3 
14 4 5 3 0 4 1 2 
15 3 3 1 1 3 3 2 
16 5 3 3 3 1 3 0 
17 5 1 3 3 1 2 2 
18 4 4 3 2 2 3 2 
19 4 3 2 3 3 1 1 
20 5 3 3 2 3 3 4 
21 5 5 3 3 1 2 1 
22 4 1 4 1 2 3 3 
23 5 4 1 2 1 2 2 
24 4 4 3 1 0 1 2 
25 3 2 5 3 2 3 1 
26 5 4 4 2 3 2 1 
27 5 4 2 3 0 3 2 
28 4 1 1 3 2 1 3 
29 3 3 1 1 1 0 2 
30 5 4 2 0 2 2 1 
Mean 4.33 3.56 3 2.03 2.1 2.1 2 
        
 Table 5 No. of comedons in each patient in group A of trial II 
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 In other group which was treated with oral Clindamycin along with 
topical Benzoyl peroxide the arithmetical mean come down to 1.1 at the end of 
sixth visit from 4.6 the mean before treatment. 
 
S.No. visit 0 visit 1 visit 2 visit 3 visit 4 visit 5 visit 6 
1 3 3 4 2 1 0 2 
2 5 4 3 3 3 0 3 
3 5 4 2 3 2 1 0 
4 4 3 3 1 1 0 1 
5 4 4 3 3 1 1 0 
6 5 3 4 0 1 3 1 
7 5 3 3 3 3 2 0 
8 4 4 4 2 0 1 0 
9 5 3 3 1 0 0 0 
10 4 4 2 2 0 1 1 
11 5 4 3 0 1 1 1 
12 5 4 2 1 1 2 1 
13 5 5 2 0 1 0 1 
14 5 4 3 0 0 1 1 
15 4 3 3 3 1 1 1 
16 5 4 4 2 1 2 2 
17 5 4 4 1 1 1 3 
18 5 3 2 1 1 1 1 
19 5 4 4 1 2 1 3 
20 4 5 3 3 1 2 1 
21 5 3 4 2 2 2 1 
22 5 4 3 0 1 0 2 
23 3 3 5 2 0 2 0 
24 5 3 3 0 3 1 0 
25 5 3 3 2 0 0 3 
26 4 4 4 1 1 1 0 
27 5 3 3 2 2 2 0 
28 5 2 2 0 1 0 2 
29 5 4 2 2 0 1 2 
30 4 2 3 1 0 1 0 
Mean 4.6 3.53 3.1 1.46 1.06 1.03 1.1 
        
 Table 6 No. of comedons in each patient in group B of trial II 
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THE EFFECT OF DRUGS ON PAPULES IN MILD CASES 
  The arithmetical mean of the number of papules in one group of 
thirty patients who receive oral Doxycycline along with topical Benzoylperoxide 
was 3.56 on ‘0’visit that is before starting therapy. The arithmetic mean at the end 
of sixth visit hss come down to 1.6.         
S.No. visit 0 visit 1 visit 2 visit 3 visit 4 visit 5 visit 6 
1 4 2 3 2 2 1 2 
2 4 3 1 3 2 1 2 
3 3 3 2 1 0 2 3 
4 4 1 2 2 3 1 2 
5 4 2 3 2 2 2 3 
6 3 3 1 1 2 2 3 
7 4 2 2 2 2 3 2 
8 4 1 2 2 1 2 2 
9 3 3 2 2 2 3 1 
10 4 2 2 1 0 3 3 
11 4 3 2 2 2 2 0 
12 3 1 2 2 1 2 2 
13 4 3 0 3 1 1 1 
14 3 2 1 2 2 3 1 
15 4 3 3 2 1 0 1 
16 3 2 2 2 2 2 0 
17 3 1 1 2 2 2 2 
18 4 3 2 0 3 1 2 
19 4 2 2 3 2 2 1 
20 3 3 3 2 3 0 2 
21 4 1 1 2 3 0 1 
22 4 3 3 2 2 1 2 
23 3 2 2 1 2 1 1 
24 4 3 2 2 1 2 1 
25 4 3 2 2 0 0 2 
26 3 3 2 0 0 2 1 
27 3 3 3 1 2 2 1 
28 4 2 1 2 1 1 1 
29 3 2 2 2 1 1 2 
30 3 2 2 0 1 0 1 
Mean 3.56 2.3 1.93 1.73 1.6 1.5 1.6 
        
 Table 7 No. of papules in each patient in group A of trial II  
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 In case of papules, the group of thirty patients treated with oral 
Clindamycin along with topical Benzoylperoxide the corresponding values are 
3.56 before therapy and 0.86 at the end of sixth week. This is also clinically 
significant. 
S.No. visit 0 visit 1 visit 2 visit 3 visit 4 visit 5 visit 6 
1 4 2 1 1 1 1 0 
2 4 3 3 2 0 1 1 
3 3 1 0 0 2 2 1 
4 4 2 2 2 0 2 0 
5 4 2 2 0 2 1 0 
6 3 1 1 2 1 1 2 
7 4 2 2 0 1 0 1 
8 4 2 0 2 0 2 2 
9 3 3 0 1 2 1 1 
10 3 4 1 2 0 1 0 
11 4 3 1 0 2 2 2 
12 3 2 2 1 2 0 0 
13 3 2 0 2 0 0 1 
14 4 3 2 1 0 0 1 
15 3 2 2 1 0 0 2 
16 3 2 1 0 2 1 1 
17 4 2 3 2 0 1 2 
18 4 2 2 3 1 1 2 
19 3 3 3 3 1 0 0 
20 4 2 3 2 0 0 1 
21 3 2 2 2 0 1 0 
22 4 2 2 1 0 0 1 
23 3 0 1 1 1 0 1 
24 3 2 3 0 2 1 1 
25 4 3 0 2 0 1 0 
26 4 2 2 2 0 0 1 
27 3 1 2 1 0 0 1 
28 4 2 1 2 0 2 0 
29 4 2 2 0 0 0 0 
30 4 1 2 1 1 0 1 
Mean 3.56 2.06 1.6 1.3 0.7 0.73 0.86 
        
 Table 8 No. of papules in each patient in group B of trial II  
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RESULTS OF TRIAL III 
THE EFFECT OF DRUGS ON COMEDONS IN MODERATE CASES OF ACNE 
  Here in the group of 30 patients who received oral Doxycycline, 
the arithmetical mean of number of comedons before therapy 4.73 and at the end 
of  sixth week it is 3.06. 
S.No. visit 0 visit 1 visit 2 visit 3 visit 4 visit 5 visit 6 
1 4 5 4 3 2 3 3 
2 5 3 4 3 3 4 3 
3 5 5 5 2 3 3 3 
4 4 5 3 3 5 2 4 
5 5 4 4 3 3 3 3 
6 4 4 3 4 3 3 4 
7 4 4 4 3 4 2 4 
8 4 4 3 4 4 3 2 
9 4 5 3 4 3 3 3 
10 5 5 4 4 4 4 3 
11 5 4 4 3 3 3 2 
12 5 4 3 4 3 4 3 
13 5 4 5 4 4 3 3 
14 4 5 4 5 3 4 2 
15 5 4 3 3 3 4 3 
16 5 5 4 4 3 2 3 
17 5 5 4 4 4 4 4 
18 5 4 3 2 3 3 3 
19 5 3 4 3 3 4 3 
20 4 5 4 3 4 3 4 
21 5 4 3 4 2 2 3 
22 5 4 4 3 4 3 4 
23 5 4 5 3 3 3 3 
24 5 3 4 3 2 2 4 
25 5 3 3 4 3 3 3 
26 5 5 5 3 2 4 3 
27 5 4 4 3 3 4 2 
28 5 3 3 2 3 3 3 
29 5 4 5 3 2 2 3 
30 5 4 4 4 3 3 2 
Mean 4.73 4.16 3.83 3.33 3.13 3.1 3.06 
        
 Table 9 No. of comedons in each patient in group A of trial III 
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  In another group of 30 patients who received only oral clindamycin 
the arithmetical mean is 4.66, before therapy has come down to 2.66 at the end 
sixth week. 
 
S.No. visit 0 visit 1 visit 2 visit 3 visit 4 visit 5 visit 6 
1 4 4 3 2 2 3 2 
2 4 1 4 3 3 2 3 
3 5 4 4 3 1 3 3 
4 5 2 3 4 4 2 2 
5 5 5 5 2 4 3 3 
6 5 4 4 3 3 4 3 
7 4 3 3 3 4 4 1 
8 5 5 4 4 3 2 3 
9 5 5 4 3 3 1 3 
10 5 2 3 3 1 3 4 
11 5 4 4 2 3 4 3 
12 5 3 4 3 3 3 1 
13 4 3 3 3 3 2 3 
14 5 4 4 4 1 3 4 
15 5 5 5 3 3 1 3 
16 4 4 4 4 3 2 1 
17 5 4 3 2 4 3 4 
18 4 5 5 4 1 3 2 
19 4 5 3 2 4 4 3 
20 4 4 4 4 3 3 3 
21 4 5 3 4 4 1 2 
22 5 4 4 5 3 3 3 
23 5 5 3 3 3 4 2 
24 5 4 3 4 4 4 2 
25 5 5 4 4 3 2 3 
26 4 5 4 2 3 1 3 
27 5 4 3 3 3 3 2 
28 5 4 5 3 4 4 3 
29 5 5 4 4 3 3 3 
30 5 4 3 2 3 2 3 
Mean 4.66 4.03 3.73 3.16 2.96 2.73 2.66 
        
 Table 10 No. of comedons in each patient in group B of trial III 
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THE EFFECT OF DRUGS ON PAPULES IN MODERATE CASES OF ACNE 
                 In case of Doxycycline treated group the arithmetical mean of 
papules on ‘0’ visit that is before drug therapy was 3.56 and at the end sixth week it 
was 2.36. 
S.No. visit 0 visit 1 visit 2 visit 3 visit 4 visit 5 visit 6 
1 4 3 3 3 2 3 2 
2 3 3 3 2 3 2 3 
3 4 2 2 3 1 3 2 
4 4 4 4 2 2 2 2 
5 3 2 2 1 2 3 2 
6 4 3 4 2 3 3 3 
7 3 3 3 1 1 4 1 
8 4 4 2 2 3 2 2 
9 4 2 4 3 2 3 2 
10 4 3 3 3 1 2 3 
11 3 4 1 1 3 3 2 
12 4 3 2 2 2 2 2 
13 2 3 2 3 2 2 2 
14 3 2 2 2 3 2 3 
15 4 3 3 3 2 2 3 
16 3 4 2 3 2 2 2 
17 4 3 3 3 3 1 3 
18 4 2 2 4 3 4 3 
19 3 3 1 3 3 3 3 
20 4 3 2 2 2 2 3 
21 4 4 3 3 2 3 2 
22 4 2 2 1 3 2 3 
23 4 3 3 2 2 3 1 
24 4 3 3 2 1 3 2 
25 3 4 3 4 3 2 3 
26 4 4 2 2 2 2 2 
27 3 4 4 1 2 3 4 
28 4 4 2 2 3 1 2 
29 3 2 4 4 4 2 2 
30 4 2 3 2 3 2 2 
Mean 3.6 3.03 2.63 2.36 2.33 2.43 2.36 
        
 Table 11 No. of papules in each patient in group A of trial III  
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 In Cindamycin treated group the corresponding values are 3.53 and 
1.96 before therapy and at the end of sixth week respectively. 
 
S.No. visit 0 visit 1 visit 2 visit 3 visit 4 visit 5 visit 6 
1 4 4 3 1 2 1 1 
2 3 2 3 2 1 1 2 
3 3 3 3 1 1 1 1 
4 4 3 3 2 3 3 1 
5 4 4 2 1 2 2 2 
6 3 3 3 2 2 3 2 
7 4 3 1 3 3 2 2 
8 2 2 2 3 2 3 3 
9 3 3 2 2 1 3 3 
10 4 3 4 2 3 2 2 
11 3 2 2 3 2 2 3 
12 4 3 2 2 2 1 3 
13 4 4 2 3 3 1 1 
14 3 3 1 3 1 2 3 
15 4 2 2 1 3 2 1 
16 4 3 2 2 3 3 1 
17 3 2 1 3 1 2 1 
18 4 3 2 2 2 3 2 
19 4 3 3 1 2 2 2 
20 2 2 2 1 1 2 3 
21 3 3 3 3 3 2 1 
22 4 4 3 3 2 2 2 
23 3 3 3 1 2 2 2 
24 4 3 3 2 1 1 3 
25 4 3 3 1 2 1 2 
26 3 3 2 2 2 1 2 
27 4 2 3 2 1 2 3 
28 4 4 3 3 0 2 2 
29 4 2 3 2 2 3 1 
30 4 2 2 3 1 1 2 
Mean 3.53 2.86 2.43 2.06 1.86 1.93 1.96 
        
 Table 12 No. of papules in each patient in group B of trial III  
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THE EFFECT OF DRUGS ON PUSTULES IN MODERATE CASES OF ACNE 
              In case of Doxycycline treated group the arithmetical mean of 
number of pustules before treatment is 3.26 and 2.03 at the end of sixth week.  
 
 
S.No. visit 0 visit 1 visit 2 visit 3 visit 4 visit 5 visit 6 
1 2 2 2 2 2 2 3 
2 3 4 3 1 2 2 4 
3 4 3 2 2 3 0 0 
4 3 3 2 3 1 2 2 
5 4 3 2 3 2 2 1 
6 2 4 3 1 2 2 1 
7 4 2 3 2 3 0 2 
8 3 3 2 2 2 3 3 
9 4 3 3 2 2 2 2 
10 2 2 3 3 2 3 2 
11 3 1 3 3 3 2 2 
12 4 3 3 3 3 3 3 
13 3 3 2 1 2 0 2 
14 4 1 3 3 3 2 3 
15 4 4 1 2 2 1 2 
16 3 2 2 1 3 2 3 
17 4 3 3 2 4 3 0 
18 4 3 3 1 3 4 2 
19 4 2 3 2 2 0 1 
20 3 2 2 2 1 2 2 
21 4 4 2 1 1 1 3 
22 3 3 3 4 2 1 4 
23 4 3 2 3 1 2 4 
24 3 2 1 2 2 3 3 
25 2 2 3 3 1 2 2 
26 3 3 2 2 2 2 1 
27 4 2 2 1 1 2 1 
28 2 1 3 2 0 1 2 
29 2 3 3 1 2 1 1 
30 4 4 3 2 1 1 0 
Mean 3.26 2.66 2.46 2.06 2 1.76 2.03 
        
 Table 13 No. of pustules in each patient in group A of trial III 
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 In Clindamycin treated group the corresponding values are 3.36 and 
1.36 before therapy and at the end of sixth week respectively 
 
S.No. visit 0 
visit 
1 visit 2 visit 3 visit 4 visit 5 visit 6 
1 3 2 1 2 1 3 0 
2 4 3 2 1 2 2 2 
3 3 3 3 0 0 0 3 
4 4 3 1 1 2 2 2 
5 4 2 1 2 1 1 3 
6 3 1 3 2 1 1 0 
7 4 3 3 2 2 2 3 
8 4 3 1 3 1 0 0 
9 4 2 2 3 2 2 2 
10 3 2 2 3 1 2 1 
11 4 3 1 1 2 0 0 
12 3 2 2 3 1 1 3 
13 4 2 3 2 0 1 1 
14 3 3 0 1 2 0 1 
15 4 3 2 2 1 1 3 
16 2 2 3 1 3 1 2 
17 4 2 3 2 1 2 1 
18 3 3 0 2 2 3 1 
19 4 3 3 1 2 2 2 
20 2 3 2 2 3 1 1 
21 3 2 3 1 2 0 0 
22 4 2 2 2 2 1 0 
23 3 3 2 3 2 0 1 
24 2 3 3 3 1 2 2 
25 2 4 3 1 2 3 1 
26 4 2 3 2 2 4 1 
27 4 2 1 2 3 0 2 
28 3 3 2 1 1 2 1 
29 4 2 3 1 0 1 0 
30 3 3 2 1 0 0 2 
Mean 3.36 2.53 2.06 1.76 1.5 1.33 1.36 
        
 Table 14 No. of pustules in each patient in group B of trial III 
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RESULTS OF TRIAL IV 
THE EFFECT OF DRUGS ON COMEDONS IN MODERATE CASES OF ACNE 
  The group treated with oral Doxycycline along with topical Benzoyl 
peroxide the arithmetical mean of number of comedons was 4.66 on “0” visit that is 
before drug therapy and 1.86 at the end of sixth week. 
 
S.No. visit 0 visit 1 visit 2 visit 3 visit 4 visit 5 visit 6 
1 4 2 5 3 1 2 1 
2 5 5 4 0 1 3 4 
3 5 4 3 2 3 4 3 
4 5 3 1 0 3 0 1 
5 5 5 4 3 2 2 3 
6 5 4 3 2 3 1 4 
7 4 1 4 4 4 3 0 
8 5 4 2 5 3 1 4 
9 5 3 3 3 2 3 3 
10 4 3 4 0 3 1 2 
11 5 4 1 3 2 2 1 
12 4 4 4 3 0 1 3 
13 4 4 3 2 3 1 1 
14 4 1 2 3 2 1 2 
15 4 4 3 3 0 0 1 
16 5 4 1 2 2 1 2 
17 5 4 3 3 3 3 0 
18 5 3 2 1 1 2 3 
19 5 3 1 0 2 1 0 
20 4 4 3 3 1 1 1 
21 5 4 1 0 3 4 3 
22 5 4 1 3 1 3 0 
23 5 4 3 3 0 0 3 
24 5 5 2 4 1 3 1 
25 5 5 0 3 3 2 3 
26 4 4 3 0 1 0 1 
27 5 4 4 3 3 1 3 
28 5 3 2 2 2 3 2 
29 4 5 4 2 3 0 1 
30 5 3 3 1 2 1 0 
Mean 4.66 3.66 2.63 2.2 2 1.66 1.86 
        
 Table 15 No. of comedons in each patient in group A of trial IV 
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 In case of oral Clindamycin along with topical Benzoyl peroxide the 
values recorded are 4.7 before therapy and 0.96 at the end of sixth week. 
 
S.No. visit 0 
visit 
1 visit 2 visit 3 visit 4 visit 5 visit 6 
1 5 3 0 3 1 1 2 
2 5 2 2 2 1 0 0 
3 5 3 4 1 0 2 1 
4 4 3 3 2 1 0 0 
5 5 4 4 3 0 1 0 
6 4 3 3 3 4 0 1 
7 4 2 2 2 0 1 1 
8 4 3 3 1 1 2 1 
9 4 3 3 2 0 3 1 
10 5 2 2 0 0 1 3 
11 5 4 3 3 1 1 1 
12 5 3 2 2 0 1 2 
13 5 4 3 2 0 3 1 
14 4 3 3 2 1 2 0 
15 5 2 2 3 1 1 0 
16 5 3 2 0 1 0 0 
17 5 3 1 3 0 1 1 
18 5 2 2 2 1 1 0 
19 5 3 3 1 1 0 1 
20 4 2 3 0 2 1 0 
21 4 3 2 2 1 1 1 
22 5 5 3 1 1 0 1 
23 4 2 1 2 2 0 1 
24 5 3 4 3 1 1 1 
25 5 3 3 1 3 0 1 
26 5 4 4 2 2 0 2 
27 5 4 3 0 0 2 1 
28 5 4 4 3 1 1 1 
29 5 3 2 2 0 1 1 
30 5 4 4 3 0 0 3 
Mean 4.7 3.06 2.66 1.86 0.9 0.93 0.96 
        
 Table 16 No. of comedons in each patient in group B of trial IV 
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THE EFFECT OF DRUGS ON PAPULES IN MODERATE CASES OF ACNE 
  In the group treated with oral Doxycycline along topical Benzoyl 
peroxide the arithmetical mean of papules in 30 patients was 3.43 before therapy 
and 1.7 at the end of sixth visit. 
 
S.No. visit 0 visit 1 visit 2 visit 3 visit 4 visit 5 visit 6 
1 2 2 1 1 2 3 2 
2 3 2 2 2 3 2 1 
3 4 3 1 1 2 0 3 
4 3 1 1 2 1 0 2 
5 4 3 2 3 1 2 0 
6 4 2 3 3 2 2 3 
7 3 3 2 1 2 0 0 
8 4 2 3 2 3 1 3 
9 4 1 3 1 0 2 2 
10 3 1 3 2 3 2 3 
11 4 2 3 3 1 3 1 
12 4 3 3 0 1 2 2 
13 2 4 2 1 3 1 2 
14 3 3 1 2 2 1 0 
15 4 2 1 3 1 2 1 
16 3 1 1 2 3 1 2 
17 4 3 2 3 2 0 2 
18 4 2 0 1 2 2 3 
19 3 1 4 3 3 1 2 
20 4 2 2 3 2 1 2 
21 4 3 1 3 2 3 3 
22 3 3 2 2 2 1 2 
23 4 2 1 1 1 3 3 
24 2 3 2 1 2 2 2 
25 3 4 1 0 1 3 1 
26 4 3 1 1 1 0 2 
27 3 2 2 2 2 1 1 
28 4 1 2 3 0 3 0 
29 3 2 2 1 1 2 0 
30 4 3 3 2 1 1 1 
Mean 3.43 2.3 1.9 1.83 1.73 1.56 1.7 
        
 Table 17 No. of papules in each patient in group A of trial IV 
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  The value for the other group treated with oral Clindamycin along with 
topical Benzoyl peroxide are 3.6 and 0.90 at the end of sixth week respectively 
 
 
S.No. visit 0 visit 1 visit 2 visit 3 visit 4 visit 5 visit 6 
1 4 2 1 1 0 0 0 
2 2 3 3 1 1 0 1 
3 3 1 1 1 1 2 2 
4 4 3 1 0 2 1 1 
5 3 2 3 2 0 0 1 
6 4 1 2 1 1 1 2 
7 4 3 1 2 2 1 1 
8 3 2 2 3 1 1 1 
9 4 3 1 0 0 0 0 
10 4 2 2 2 1 0 1 
11 3 3 2 2 1 2 0 
12 4 1 0 0 1 1 0 
13 4 2 2 2 0 2 1 
14 3 3 1 1 1 1 0 
15 4 4 2 1 1 0 1 
16 3 3 0 0 1 1 1 
17 4 2 2 1 2 0 1 
18 4 1 0 1 0 1 2 
19 4 2 2 0 1 2 2 
20 4 1 0 1 0 1 1 
21 4 3 0 2 0 2 1 
22 4 1 3 0 1 0 0 
23 4 3 1 0 1 1 1 
24 4 1 3 1 1 1 1 
25 4 1 2 1 1 1 0 
26 2 2 0 0 1 2 1 
27 3 1 2 1 2 1 2 
28 4 3 1 2 0 1 2 
29 3 1 2 2 1 0 0 
30 4 3 1 0 1 1 0 
Mean 3.6 2.1 1.43 1.03 0.86 0.9 0.9 
        
 Table 18 No. of papules in each patient in group B of trial IV 
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THE EFFECT OF DRUGS ON PUSTULES IN MODERATE CASES OF ACNE 
  The arithmetical mean of the number of pustules in the group treated 
with oral Doxycycline along with topical Benzoyl peroxide is seen as 3.3 before 
therapy and 1.06 at the end of sixth week. 
   
S.No. visit 0 visit 1 visit 2 visit 3 visit 4 visit 5 visit 6 
1 4 1 2 1 1 0 0 
2 4 2 3 0 3 1 2 
3 3 2 0 1 1 1 0 
4 4 4 2 2 0 1 0 
5 3 1 3 0 2 1 2 
6 4 3 0 1 1 3 1 
7 3 2 3 2 0 2 0 
8 4 0 3 1 2 0 3 
9 2 3 2 0 2 2 1 
10 4 2 3 3 1 1 1 
11 3 0 1 0 2 0 1 
12 4 3 2 1 2 2 2 
13 2 3 0 0 1 1 1 
14 3 0 3 2 1 0 1 
15 4 1 0 1 0 3 1 
16 3 3 1 1 0 1 1 
17 3 0 0 2 1 1 0 
18 2 2 1 0 1 2 0 
19 4 3 2 3 1 0 1 
20 4 3 3 1 0 2 1 
21 3 2 2 1 0 2 1 
22 3 1 2 3 1 0 2 
23 4 0 3 1 3 2 0 
24 4 3 2 1 1 0 0 
25 3 1 0 2 0 1 3 
26 4 4 1 1 2 1 2 
27 3 2 2 1 0 1 3 
28 4 2 0 2 0 0 0 
29 2 1 1 1 0 2 1 
30 2 2 1 2 0 0 1 
Mean 3.3 1.86 1.6 1.23 0.96 1.1 1.06 
        
 Table 19 No. of pustules in each patient in group A of trial IV 
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 In the group treated with oral Clindamycin along with topical Benzoyl 
peroxide the values are 3.43 before therapy and 0.43 at the end of sixth week. 
 
S.No. visit 0 visit 1 visit 2 visit 3 visit 4 visit 5 visit 6 
1 4 3 0 0 0 0 0 
2 3 2 1 0 0 1 0 
3 4 0 1 2 0 1 0 
4 3 3 2 1 1 1 1 
5 2 1 1 0 1 0 2 
6 2 2 0 0 1 0 0 
7 4 0 0 0 0 0 0 
8 4 3 2 1 0 0 0 
9 4 3 2 1 1 1 0 
10 4 1 0 0 0 1 1 
11 4 1 2 1 1 0 2 
12 4 2 3 1 0 0 0 
13 3 2 0 2 0 0 0 
14 4 1 2 1 1 0 1 
15 4 0 0 0 1 1 0 
16 4 2 1 1 0 1 0 
17 2 2 1 1 0 1 0 
18 4 3 2 0 2 1 1 
19 3 0 0 2 0 0 1 
20 4 2 0 1 2 1 0 
21 2 1 2 0 0 0 0 
22 4 1 1 1 0 0 0 
23 3 2 1 1 0 1 0 
24 4 2 1 0 0 0 0 
25 2 3 1 1 1 0 1 
26 4 2 0 1 0 1 0 
27 4 0 0 0 1 1 1 
28 3 1 1 1 0 0 0 
29 3 0 0 0 0 1 2 
30 4 1 1 0 1 0 0 
Mean 3.43 1.53 0.93 0.66 0.46 0.46 0.43 
        
 Table 20 No. of pustules in each patient in group B of trial IV 
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STATISTICAL ANALYSIS 
  Statistical analysis is done by using independent student t- test and 
the ‘P’ values are determined. 
TRIAL I 
Comparision of number of comedons between group A & B of trial I 
 
 group N Mean 
Std. 
Deviation 
Student 
Independent  t-test  
visit 0 D 30 4.40 .699 T=0.23 
P=0.82 
NOT SIGNIFICANT 
  C 30 4.33 .702 
visit 1 D 30 4.00 .810 T=2.11 
P=0.04 
SIGNIFICANT 
  C 30 3.43 1.338 
visit 2 D 30 3.80 .740 T=3.38 
P=0.001 
SIGNIFICANT 
  C 30 3.06 1.153 
visit 3 D 30 3.40 .708 T=2.05 
P=0.04 
SIGNIFICANT 
  C 30 2.93 1.048 
visit 4 D 30 3.16 .635 T=1.86 
P=0.05 
SIGNIFICANT 
  C 30 2.86 .860 
visit 5 D 30 3.13 .723 T=2.83 
P=0.001 
SIGNIFICANT 
  C 30 2.96 .720 
visit 6 D 30 3.06 .637 T=3.73 
P=0.001 
SIGNIFICANT 
  C 30 2.83 .672 
 
 
 
   
 Table 21 shows comparison done in relation to number of comedons 
between group A and B, which received oral Doxycycline and oral Clindamycin 
respectively. The ‘P’ value at the end of sixth week is 0.001 which is significant.  
 
 
Table 21. Comparision of no. of comedons between group A & B of trial I. 
D- Doxycyclin, C- Clindamycin. 
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D = DOXYCYCLINE,      C = CLINDAMYCIN 
 
Figure 1 shows Reduction in number of comedons in Trial I 
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Comparision of number of papules between group A & B of trial I 
 
 group N Mean 
Std. 
Deviation 
Student 
Independent 
 t-test  
visit 0 D 30 3.30 .728 T=0.48 
P=0.63 
NOT-
SIGNIFICANT 
  C 
30 3.36 .667 
visit 1 D 30 2.73 .674 T=1.76 
P=0.48 
NOT-
SIGNIFICANT 
  C 
30 2.40 .720 
visit 2 D 30 2.50 .834 T=1.87 
P=0.07 
NOT-
SIGNIFICANT 
  C 
30 2.10 .670 
visit 3 D 30 2.33 .747 T=1.99 
P=0.05 
SIGNIFICANT 
  C 30 2.06 .790 
visit 4 D 30 2.33 .795 T=2.01 
P=0.04 
SIGNIFICANT 
  C 30 1.83 .846 
visit 5 D 30 2.16 .740 T=2.01 
P=0.04 
SIGNIFICANT 
  C 30 1.93 .870 
visit 6 D 30 2.20 .683 T=2.02 
P=0.05 
SIGNIFICANT 
  C 30 1.90 .806 
 
 
 
 
 
  The table No.22 shows comparison between Doxycycline and 
Clindamycin orally treated groups in Trial I, for papules,  the ‘P’ value at the end of 
sixth week is 0.05 which is significant. 
Table 22. Comparision of no. of papules between group A & B of trial I.  
D- Doxycyclin, C- Clindamycin. 
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D =DOXYCYCLINE, C = CLINDAMYCINE. 
Figure 2 shows Reduction in number of papules in Trial I 
 
 
 
 
 
 
 
 
 
 58
 
Trial  II 
Comparision of number of comedons between group A & B of trial II 
 
 group N Mean 
Std. 
Deviation 
Student 
Independent 
 t-test  
visit 0 D+B 30 4.33 .745 T=1.46 
P=0.15 
NOT-
SIGNIFICANT 
  C+B 
30 4.60 .615 
visit 1 D+B 30 3.56 1.135 T=0.26 
P=0.79 
NOT-
SIGNIFICANT 
  C+B 
30 3.53 .761 
visit 2 D+B 30 3.00 1.092 T=0.08 
P=1.00 
NOT-
SIGNIFICANT 
  C+B 
30 3.10 .933 
visit 3 D+B 30 2.03 1.088 T=2.34 
P=0.02 
SIGNIFICANT 
  C+B 30 1.46 1.047 
visit 4 D+B 30 2.10 1.162 T=3.88 
P=0.001 
SIGNIFICANT 
  C+B 30 1.06 .878 
visit 5 D+B 30 2.10 1.121 T=4.07 
P=0.001 
SIGNIFICANT 
  C+B 30 1.03 .822 
visit 6 D+B 30 2.00 1.031 T=3.63 
P=0.001 
SIGNIFICANT 
  C+B 30 1.10 1.031 
 
 
 
  In trial II, that is the group which has been treated oral Doxycyclin 
along with topical Benzoyl peroxide is compared with the other group treated withoral 
Clindamycin along with topical Benzoyl peroxide. The ‘P’ value at the end of sixth 
week in case of Comedon is 0.001, which is significant shown in table 23. 
Table 23. Comparision of no. of comedons between group A & B of trial II. 
D- Doxycyclin, C- Clindamycin, B- Benzoyl peroxiode 
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D =DOXYCYCLINE,  C = CLINDAMYCIN, B = BENZOIL PEROXIDE 
 
Figure 3 shows Reduction in number of comedons in Trial II 
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Comparision of number of papules between group A & B of trial II 
 
 group N Mean 
Std. 
Deviation 
Student 
Independent 
 t-test  
visit 0 D+B 30 3.56 .504 T=0.25 
P=0.81 
NOT-
SIGNIFICANT 
  C+B 
30 3.56 .507 
visit 1 D+B 30 2.30 .738 T=1.48 
P=0.14 
NOT-
SIGNIFICANT 
  C+B 
30 2.06 .782 
visit 2 D+B 30 1.93 .734 T=1.73 
P=0.08 
NOT-
SIGNIFICANT 
  C+B 
30 1.60 .983 
visit 3 D+B 30 1.73 .780 T=1.90 
P=0.06 
NOT-
SIGNIFICANT 
  C+B 
30 1.30 .924 
visit 4 D+B 30 1.60 .950 T=3.66 
P=0.001 
SIGNIFICANT 
  C+B 30 .70 .821 
visit 5 D+B 30 1.50 .915 T=3.63 
P=0.001 
SIGNIFICANT 
  C+B 30 .73 .729 
visit 6 D+B 30 1.60 .840 T=3.54 
P=0.001 
SIGNIFICANT 
  C+B 30 .86 .707 
 
 
 
 
  In case of papules, the ‘P’ value determined at the end of sixth week is 
0.001, which is also significant shown in table 24. 
 
 
 
Table 24. Comparision of no. of papules between group A & B of trial II.  
D- Doxycyclin, C- Clindamycin, B- Benzoyl peroxiode 
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D = DOXYCYCLINE, C = CLINDAMYCINE, B = BENZOIL PEROXIDE. 
Figure 4 shows Reduction in number of papules in Trial II 
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TRIAL III 
Comparision of number of comedons between group A & B of trial III 
 
 group N Mean 
Std. 
Deviation 
Student 
Independent 
 t-test  
visit 0 D 30 4.73 .407 T=0.81 
P=0.42 
NOT-
SIGNIFICANT 
  C 
30 4.66 .461 
visit 1 D 30 4.16 .871 T=0.27 
P=0.79 
NOT-
SIGNIFICANT 
  C 
30 4.03 .964 
visit 2 D 30 3.83 .714 T=0.6 
P=0.59 
NOT-
SIGNIFICANT 
  C 
30 3.73 .871 
visit 3 D 30 3.33 .774 T=1.96 
P=0.45 
NOT-
SIGNIFICANT 
  C 
30 3.16 1.140 
visit 4 D 30 3.13 .699 T=1.96 
P=0.05 
SIGNIFICANT 
  C 30 2.96 .714 
visit 5 D 30 3.10 .718 T=2.47 
P=0.01 
SIGNIFICANT 
  C 30 2.73 0.72 
visit 6 D 30 3.06 .626 T=1.96 
P=0.05 
SIGNIFICANT 
  C 30 2.66 .73 
 
 
 
  In trial III, one group has received oral doxycyclin and other group has 
received oral Clindamycin in moderate cases of Comedons of acne vulgaris, the ‘P’ 
value in case of Comedon at the end of sixth week is 0.05, which is significant and is 
shown in table 25. 
 
Table 25. Comparision of no. of comedons between group A & B of trial 
III. D- Doxycyclin, C- Clindamycin. 
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D = DOXYCYCLINE,  C = CLINDAMYCIN.  
 
Figure 5 shows Reduction in number of comedons in Trial III. 
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Comparision of number of papules between group A & B of trial III 
 
 
GROU
P N Mean 
Std. 
Deviation 
Student 
Independent 
 t-test  
visit 0 D 30 3.60 .619 T=0.18 
P=0.86 
NOT-
SIGNIFICANT 
  C 
30 3.53 .629 
visit 1 D 30 3.03 .759 T=1.07 
P=0.29 
NOT-
SIGNIFICANT 
  C 
30 2.86 .681 
visit 2 D 30 2.63 .878 T=0.63 
P=0.53 
NOT-
SIGNIFICANT 
  C 
30 2.43 .728 
visit 3 D 30 2.36 .911 T=1.57 
P=0.12 
NOT-
SIGNIFICANT 
  C 
30 2.06 .785 
visit 4 D 30 2.33 .738 T=2.25 
P=0.03 
SIGNIFICANT 
  C 30 1.86 .819 
visit 5 D 30 2.43 .716 T=2.73 
P=0.01 
SIGNIFICANT 
  C 30 1.93 .740 
visit 6 D 30 2.36 .712 T=2.34 
P=0.02 
SIGNIFICANT 
  C 30 1.96 .765 
 
 
 
 
 
  The ‘P’ value in case of papules at the end of sixth week is 0.02, which 
is significan and is shown in table 26. 
 
 
 
Table 26. Comparision of no. of papules between group A & B of trial III.  
D- Doxycyclin, C- Clindamycin. 
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D = DOXYCYCLINE, C = CLINDAMYCINE. 
 
Figure 6 shows Reduction in number of papules in Trial III 
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Comparision of number of pustules between group A & B of trial III 
 
 group N Mean 
Std. 
Deviation 
Student 
Independent 
 t-test  
visit0 D 30 3.26 .77186 T=0.45 
P=0.65 
NOT-
SIGNIFICANT 
  C 
30 3.36 .71840 
visit1 D 30 2.66 .88843 T=0.94 
P=0.34 
NOT-
SIGNIFICANT 
  C 
30 2.53 .62881 
visit2 D 30 2.46 .66524 T=1.64 
P=0.10 
NOT-
SIGNIFICANT 
  C 
30 2.06 .94443 
visit3 D 30 2.06 .81752 T=1.57 
P=0.12 
NOT-
SIGNIFICANT 
  C 
30 1.76 .81720 
visit4 D 30 2.0 .87759 T=1.98 
P=0.05 
SIGNIFICANT 
  C 30 1.50 .86103 
visit5 D 30 1.76 .99139 T=1.99 
P=0.05 
SIGNIFICANT 
  C 30 1.33 1.09334 
visit6 D 30 2.03 1.16224 T=2.04 
P=0.04 
SIGNIFICANT 
  C 30 1.36 1.03335 
 
 
 
 
  In case of pustules, the ‘P’ value at the end of sixth week is 0.04, 
which is significant and is shown in table  27. 
Table 27. Comparision of no. of pustules between group A & B of trial III.  
D- Doxycyclin, C- Clindamycin. 
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  D = DOXYCYCLINE, C = CLINDAMYCIN. 
 Figure 7 shows Reduction in number of pustules in Trial III 
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TRIAL IV 
Comparision of number of comedons between group A & B of trial IV 
 group N Mean 
Std. 
Deviation 
Student 
Independent 
 t-test  
visit 0 D+B 30 4.66 .486 T=0.56 
P=0.57 
NOT-
SIGNIFICANT 
  C+B 
30 4.70 .460 
visit 1 D+B 30 3.66 1.029 T=1.38 
P=0.17 
NOT-
SIGNIFICANT 
  C+B 
30 3.06 .819 
visit 2 D+B 30 2.63 1.285 T=0.33 
P=0.74 
NOT-
SIGNIFICANT 
  C+B 
30 2.66 .905 
visit 3 D+B 30 2.20 1.264 T=1.45 
P=0.15 
NOT-
SIGNIFICANT 
  C+B 
30 1.86 1.020 
visit 4 D+B 30 2.00 1.108 T=3.05 
P=0.003 
SIGNIFICANT 
  C+B 30 .90 .999 
visit 5 D+B 30 1.66 1.301 T=2.33 
P=0.02 
SIGNIFICANT 
  C+B 30 0.93 .861 
visit 6 D+B 30 1.86 1.279 T=2.11 
P=0.04 
SIGNIFICANT 
  C+B 30 0.96 .881 
 
 
 
 
 
 
  One group which receives oral Doxycycline along with topical Benzoyl 
peroxide is compared to other group which has received oral Clindamycin and 
topical Benzoyl peroxide. This group includes only moderate cases. In case of 
Comedon, the ‘P’ value at the end of sixth week is 0.04, which is significant, shown 
in table 28. 
 
 
Table 28. Comparision of no. of comedons between group A & B of trial IV. 
D- Doxycyclin, C- Clindamycin, B- Benzoyl peroxide 
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D = DOXYCYCLINE, C = CLINDAMYCINE, B = BENZOIL PEROXIDE. 
 
Figure 8 shows Reduction in number of comedons in Trial IV 
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Comparision of number of papules between group A & B of trial IV 
 
 
GROU
P N Mean 
Std. 
Deviation 
Student 
Independent 
 t-test  
visit 0 D+B 30 3.43 .672 T=1.27 
P=0.21 
NOT-
SIGNIFICANT 
  C+B 
30 3.60 .609 
visit 1 D+B 30 2.30 .871 T=0.88 
P=0.38 
NOT-
SIGNIFICANT 
  C+B 
30 2.10 .907 
visit 2 D+B 30 1.90 .908 T=2.22 
P=0.04 
SIGNIFICANT 
  C+B 30 1.43 .976 
visit 3 D+B 30 1.83 .934 T=3.34 
P=0.001 
SIGNIFICANT 
  C+B 30 1.03 .822 
visit 4 D+B 30 1.73 .855 T=4.76 
P=0.001 
SIGNIFICANT 
  C+B 30 .86 .628 
visit 5 D+B 30 1.56 1.029 T=2.89 
P=0.005 
SIGNIFICANT 
  C+B 30 .90 .707 
visit 6 D+B 30 1.70 1.013 T=3.54 
P=0.001 
SIGNIFICANT 
  C+B 30 .90 .689 
 
 
 
  In case of papules, the ‘P’ value at the end of sixth week is 0.001, 
which is significant, shown in table 29. 
 
 
 
 
 
 
Table 29. Comparision of no. of papules between group A & B of trial IV. 
D- Doxycyclin, C- Clindamycin, B- Benzoyl peroxide 
 71
0
1
2
3
4
M
ea
n 
nu
m
be
r o
f l
es
io
ns
D+B C+B D+B C+B D+B C+B D+B C+B D+B C+B D+B C+B D+B C+B
visit0 visit1 visit2 visit3 visit4 visit5 visit6
PAPULES IN ACNEVULGARIS(Moderate)
 
 
 
D = DOXYCYCLINE, C = CLINDAMYCINE, B =BENZOIL PEROXIDE. 
 
Figure 9 shows Reduction in number of papules in Trial IV 
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Comparision of number of pustules between group A & B of trial IV 
 
 group N Mean 
Std. 
Deviation 
Student 
Independent 
 t-test  
visit0 D+B 30 3.30 .73908 T=0.60 
P=0.85 
NOT 
SIGNIFICANT 
  C+B 
30 3.43 .79755 
visit1 D+B 30 1.86 1.18594 T=1.31 
P=0.19 
NOT-
SIGNIFICANT 
  C+B 
30 1.53 1.04679 
visit2 D+B 30 1.60 1.11587 T=2.93 
P=0.005 
SIGNIFICANT 
  C+B 30 0.93 .87067 
visit3 D+B 30 1.23 .90992 T=2.85 
P=0.006 
SIGNIFICANT 
  C+B 30 0.66 .65991 
visit4 D+B 30 0.96 .91228 T=2.71 
P=0.009 
SIGNIFICANT 
  C+B 30 0.46 .61892 
visit5 D+B 30 1.10 .90755 T=2.74 
P=0.008 
SIGNIFICANT 
  C+B 30 0.46 .61892 
visit6 D+B 30 1.06 .94812 T=2.67 
P=0.01 
SIGNIFICANT 
  C+B 30 0.43 .71772 
 
 
 
 
  In case of pustules, the ‘P’ value at the end of sixth week is 0.001, 
which is significant, shown in table 30. 
 
 
 
 
Table 30. Comparision of no. of pustules between group A & B of trial IV. 
D- Doxycyclin, C- Clindamycin, B- Benzoyl peroxide 
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D = DOXYCYCLINE, C =CLINDAMYCINE, B = BENZOIL PEROXIDE. 
 
Figure 10 shows reduction in number of pustules in Trial IV. 
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Results of Adverse effects 
  The patients were also followed up for the occurance of adverse 
effects. In fact one of the objective of the study is to find out, if Clindamycin is 
producing good results without causing unwanted effects when given in low doses of 
orally for a period of four weeks. 
ADVERSE  
EFFECTS 
0 VISIT 1ST 
VISIT 
2ND 
VISIT  
3RD 
VISIT 
4TH 
VISIT 
5TH 
VISIT 
6TH 
VISIT 
TOTAL 
NO. 
OF 
CASES 
RASHES 0 0 0 0 0 0 0 0 
URTICARIA 0 0 0 0 0 0 0 0 
NAUSEA 0 1 1 2 1 2 2 9 
VOMITING 0 1 2 1 1 1 1 7 
ABDOMINAL 
PAIN  
0 1 1 2 1 2 1 8 
DIARRHOEA 0 0 1 1 1 1 2 6 
DYSENTRY 0 0 1 1 1 1 1 5 
DIZZINESS 0 0 0 0 0 0 0 0 
 
 
    Table 31 shows the occurance of adverse effects in the study group 
treated with Clindamycin. 
  The table shows the number of cases complaining of adverse effects 
mentioned during each visit for a period of six weeks. 
  The total number of patients reported with Nausea were 9, Vomiting  
were 7, Abdominal pain  8, Diarrhoea  6 and Dysentry 5. 
 
 
 
 
Table 31. Adverse effects with clindamycin 
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7. DISCUSSION 
  The objective of the study is not only to find out the efficacy of a low 
dose of 50 mg Clindamycin given orally, but also to find out if this efficacy is obtained 
without producing the adverse effects for which the administration of Clindamycin is 
hesitated. The worst complication is pseudomembranous entero colitis.  
  Clindamycin produces very good effect in acne vulgaris and this is 
discussed later. These effects are produced without significant adverse effects.  
  In few cases reported as Nausea, Vomiting, Diarrhoea were clinically 
insignificant and they were self limiting. The patients revealed the occurrence of such 
effects only after questioning them specifically for such an effect.  
  If Diarrhoea, Abdominal pain had been severe they would have 
definitely reported to the investigator but no one reported. And all of them continued 
to take the drug without stopping. Here also it should be noted that if Nausea and 
Vomiting had been due to Pseudomembranous enterocolitis, the condition would 
have worsened with continuous intake.  
  But the symptoms were self limiting. Only three cases of Dysentry 
were prescribed tablet Metronidazole by their own doctor. 
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  on analyzing the efficacy of oral Clindamycin, a low dose that is 50 mg 
administered daily for four weeks has definitely produced better results than 
Doxycycline administered as a single daily dose for 4 weeks. 
  There is significant reduction in the number of Comedons and papules 
in mild cases of acne vulgaris who have received only oral Clindamycin when 
compared to other group who have received only oral Doxycycline. 
  This is evident both in the clinical data which has been presented 
under the results column and also has been found to be statistically significant. 
                       In moderate cases, also the significant improvement is seen in the 
group which is treated with oral Clindamycin. This is reflected as reduction in the 
number of Comedons, papules and pustules in the Clindamycin treated group, when 
compared to the other group which is Doxycycline treated control group. The role of 
Propionibacterium acne in pathogenesis of acne has already been discussed.  
                       The anti microbials, Cap.Doxycycline and Cap.Clindamycin act in 
acne vulgaris by their effect on the Propionibacterium acne. 
  These antibiotics decrease the population of Propionibacterium acne 
which in turn leads to the inhibition of the bacterial lipases and this is followed by a 
decrease in concentration of free fatty acids .This produces less tissue inflammation 
and acne.  
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  Since topically applied drugs are widely used in therapy of acne, in the 
trial groups in which the oral drug therapy was combined with topical Benzoyl 
peroxide and the outcome was analyzed. 
  Greater efficacy was obtained when oral Clindamycin was combined 
with topical Benzoyl peroxide.  Doxycycline when used alone or in combination with 
Benzoyl peroxide has retained its efficacy, and the efficacy is greater when 
combined with topical Benzoyl peroxide.  
                        Clindamycin either alone or in combination with topical Benzoyl 
peroxide 5% cream shows greater efficacy than Doxycycline either alone or in 
combination with topical Benzoyl peroxide 5% cream. The reason for lesser efficacy 
of Doxycycline could be due to development of resistance by Propionibacterium 
acne in some of the patients included in this trial. 
  The literature tells that there is increase in the resistance of 
Propionibacterium acne to antibiotics worldwide.  
         Clindamycin, though an anti microbial, shows greater efficacy in this 
study. This could be because Clindamycin oral therapy has not been used so far for 
acne vulgaris and probably the bacteria have not developed resistance. 
  The better results obtained in a group which has been treated with 
topical Benzoyl peroxide group could be definitely due to its anti bacterial action and 
direct anti inflammatory action.  
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8. CONCLUSION 
The study has proved that a low dose of 50 mg of oral Clindamycin 
administered once a day for four weeks produces good results in acne vulgaris. The 
good results are obtained without unwanted adverse reactions. For many infections 
150 to 300 mg are given 3 – 4 times a day produces many adverse effects. 
In this trial the low dose of 50 mg used is not only highly effective, but 
also has not produced any significant adverse reactions. So far, the Clindamycin has 
only been used topically for acne vulgaris. This study encourages the use of  low 
dose oral  Clindamycin in acne vulgaris.  
                      Future trials using Clindamycin in combination with the other topical 
agents like Tretinoin and Adapalene which have different mechanism of actions can 
be tried. Tretinoin reverses abnormal keratinizing changes in acne vulgaris. 
Adapalene has got comedolytic property.  
This trial has been conducted as single centre trial and similar trials 
will promote wider use of oral Clindamycin in acne vulgaris. 
This study proves the safety and efficacy of low dose of oral 
Clindamycin in acne vulgaris, and such low doses can also be tried for other 
infections where the causative organism responds to Clindamycin. 
 
 
The following photos show Grade I & II case of Acne vulgaris in trail I & III 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Before administration of oral Doxycycline 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
After four weeks administration of oral Doxycycline  
 
 
 
The following photos show Grade I & II case of Acne vulgaris in trail II and IV 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Before administration of oral Doxycycline with 5% Benzoil peroxide 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
After four weeks administration of oral Doxycycline with 5% Benzoil peroxide 
 
 
 
 
 
 
The following photos show Grade I & II case of Acne vulgaris in trail I & III 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Before administration of oral Clindamycin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
After four weeks administration of oral Clindamycin 
 
 
 
 
 
 
The following photos show Grade I & II case of Acne vulgaris in trial II & IV 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Before administration of oral Clindamycin with 5% Benzoil peroxide 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
After four weeks administration of oral Clindamycin with 5% Benzoil peroxide 
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                                         APPENDIX  I 
 
 
                            Informed written consent form 
 
 
I                                                willing to participate in this study titled;the  
 
study of oral clindamycin in Acne vulgaris at my own will. I have  
 
understood the importance of this study.The objectives,importance and  
 
details of this study have been explained to me clearly by the investigator  
 
Dr.N.Arivazhagan, in my mother tongue. I am aware that if I wish to  
 
discontinue from the study at any point of time, I can do so. I also give  
 
permission to the researcher to use my medical records for any sort of  
 
publication.  
 
 
 
 
 Signature of the subject (or) 
Date                                                                         Of the parent/guardian . 
